115 related articles for article (PubMed ID: 18703367)
1. Insulin glargine has a long duration of effect following administration either once daily or twice daily in divided doses in healthy cats.
Marshall RD; Rand JS; Morton JM
J Feline Med Surg; 2008 Oct; 10(5):488-94. PubMed ID: 18703367
[TBL] [Abstract][Full Text] [Related]
2. Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats.
Marshall RD; Rand JS; Morton JM
J Vet Pharmacol Ther; 2008 Jun; 31(3):205-12. PubMed ID: 18471141
[TBL] [Abstract][Full Text] [Related]
3. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
Ashwell SG; Gebbie J; Home PD
Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats: findings during the first week and after 5 or 9 weeks of therapy.
Martin GJ; Rand JS
J Feline Med Surg; 2001 Mar; 3(1):23-30. PubMed ID: 11716627
[TBL] [Abstract][Full Text] [Related]
5. Treatment of newly diagnosed diabetic cats with glargine insulin improves glycaemic control and results in higher probability of remission than protamine zinc and lente insulins.
Marshall RD; Rand JS; Morton JM
J Feline Med Surg; 2009 Aug; 11(8):683-91. PubMed ID: 19539509
[TBL] [Abstract][Full Text] [Related]
6. Effects of diet on glucose control in cats with diabetes mellitus treated with twice daily insulin glargine.
Hall TD; Mahony O; Rozanski EA; Freeman LM
J Feline Med Surg; 2009 Feb; 11(2):125-30. PubMed ID: 18835801
[TBL] [Abstract][Full Text] [Related]
7. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H
Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999
[TBL] [Abstract][Full Text] [Related]
8. Glucose lowering effects of inhaled insulin in healthy cats.
DeClue AE; Leverenz EF; Wiedmeyer CE; Bryan ME; Reinero CR
J Feline Med Surg; 2008 Oct; 10(5):519-22. PubMed ID: 18602326
[TBL] [Abstract][Full Text] [Related]
9. Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusion.
Scholtz HE; Pretorius SG; Wessels DH; Venter C; Potgieter MA; Becker RH
Acta Diabetol; 2003 Dec; 40(4):156-62. PubMed ID: 14740274
[TBL] [Abstract][Full Text] [Related]
10. Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects.
Becker RH; Frick AD; Teichert L; Nosek L; Heinemann L; Heise T; Rave K
Diabetes Obes Metab; 2008 Nov; 10(11):1105-13. PubMed ID: 18355326
[TBL] [Abstract][Full Text] [Related]
11. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
[TBL] [Abstract][Full Text] [Related]
12. Insulin glargine improves glycaemic control after coronary surgery in patients with diabetes or pre-diabetes.
Hagelberg A; Ivert T; Efendić S; Ohrvik J; Anderson RE
Scand Cardiovasc J; 2008 Feb; 42(1):71-6. PubMed ID: 18273733
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes.
Hompesch M; Ocheltree SM; Wondmagegnehu ET; Morrow LA; Kollmeier AP; Campaigne BN; Jacober SJ
Curr Med Res Opin; 2009 Nov; 25(11):2679-87. PubMed ID: 19761358
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.
Porcellati F; Rossetti P; Ricci NB; Pampanelli S; Torlone E; Campos SH; Andreoli AM; Bolli GB; Fanelli CG
Diabetes Care; 2007 May; 30(5):1261-3. PubMed ID: 17303785
[No Abstract] [Full Text] [Related]
15. Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice.
Yamanaka M; Itakura Y; Ono-Kishino M; Tsuchida A; Nakagawa T; Taiji M
J Biosci Bioeng; 2008 Apr; 105(4):395-402. PubMed ID: 18499057
[TBL] [Abstract][Full Text] [Related]
16. Twice-daily variable insulin regimens: proportions of insulin types have little impact on glycaemic control in primary school-aged children.
McDonnell CM; Donath SM; Werther GA; Cameron FJ
Diabet Med; 2008 Sep; 25(9):1112-6. PubMed ID: 19183317
[TBL] [Abstract][Full Text] [Related]
17. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
Thorisdottir RL; Parkner T; Chen JW; Ejskjaer N; Christiansen JS
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369
[TBL] [Abstract][Full Text] [Related]
18. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
20. Peripheral and centrally mediated effects of insulin on small intestinal transit in healthy mice.
Peddyreddy MK; Rao KR
Clin Exp Pharmacol Physiol; 2006 Jul; 33(7):633-6. PubMed ID: 16789932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
